Silver Spring, MD—FDA is reopening the comment period for last year’s CBD hearing.
The hearing was intended to obtain scientific data and information about the safety, manufacturing, product quality, marketing, labeling, and sale of products containing cannabis or cannabis-derived compounds; the docket for public comment was supposed to close on July 2, 2019, but the comment period was extended to July 16, 2019. As of today, the comment period has been reopened, and the FDA is “extending it indefinitely.”
Related: UK Sets Upper Limit for CBD, Deadline for Authentication
FDA Releases Statement Regarding CBD; Industry Reacts
Utah Passes Resolution Asking Congress, President for Safe CBD Legislation
Daniel Fabricant, Ph.D., President and CEO of the Natural Products Association, said in a release: “This is a huge and surprising step backwards. Reopening the comment period will do nothing to protect public health when the FDA is already sitting on a ticking time bomb. The longer FDA waits, the greater risk we have of seeing another public health crisis. If the FDA wants to do something constructive, then it can get to work on setting a safe level of daily consumption for CBD.”